Skip to content

EveryLife submitted comments to inform the FDA on the Patient-Focused Drug Development Guidance

Share this page

Comments to inform the U.S. Food and Drug Administration on the “Patient-Focused Drug Development Guidance 4: Incorporating Clinical Outcome Assessments into Endpoints for Regulatory Decision Making”.

Related Articles